混合模型框架下的模型，如潜变量增长混合模型（latent growth mixture modeling，LGMM）或潜类别增长分析（latent class growth analysis，LCGA），因估算过程中涉及多个决策过程，导致潜变量轨迹分析结果的报告呈现多样性。为解决这一问题，指南制订小组按照系统化的制订流程，通过 4 轮德尔菲法调查，遵循专家小组意见，提出了各领域报告潜变量轨迹分析结果时需采用统一的标准，最终确定了报告轨迹研究结果必要的关键条目，发布了潜变量轨迹研究报告规范（guidelines for reporting on latent trajectory studies，GRoLTS），并利用 GRoLTS 评价了 38 篇使用 LGMM 或 LCGA 研究创伤后应激轨迹的论文的报告情况。
ObjectiveTo systematically review the efficacy of treatments for β-coronaviruses.MethodsPubMed, EMbase, Web of Science, The Cochrane Library, SinoMed, CNKI and WanFang Data databases were electronically searched to collect randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) of treatments for β-coronaviruses from inception to June 17th, 2020. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 14.0 software.ResultsA total of 109 studies invoving 23 210 patients were included. The results of the systematic review showed that compared with standard of care, corticosteroids could reduce mortality and increase cure rate for COVID-19. However, chloroquine could decrease cure rate. In severe acute respiratory syndrome (SARS) patients, corticosteroids could decrease the cure rate. In Middle East respiratory syndrome (MERS) patients, ribavirin/interferon/both drugs showed higher mortality.ConclusionsThe currently limited evidence shows that corticosteroids may be effective to COVID-19 patients while having limited effects on SARS patients. Hydroxychloroquine or chloroquine may have negative effects on COVID-19 patients. Ribavirin/interferon may be harmful to MERS patients. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusions.